ROCKVILLE, Maryland,
Sept. 10, 2013 /PRNewswire/
-- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of
biologics focused on the prevention and treatment of serious
infectious diseases, announced today that Jeffrey Riley, CEO, will present at the First
Global Life Sciences Conference to be held on September 16-17, 2013 in Warsaw, Poland. Mr. Riley is scheduled to
present at 11:15 a.m. (Central
European Summer Time)/5:15 a.m. (Eastern
Time) on Monday, September 16,
2013 at the Warsaw Stock Exchange.
(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
)
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the internet at
http://www.wdmcapital.com/en/strony/lsc/live_webcast.html. After
the presentation, a replay will be archived and accessible for 30
days at the same website.
Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to
participate in one-on-one meetings with conference attendees. To
arrange a one-on-one meeting with Synthetic Biologics, please
contact Wojciech Grzegorczyk at
wojciech.grzegorczyk@wdmsa.pl or by phone +48 784 094
599.
WDM Capital, a prominent small cap investment bank in Central
and Eastern Europe, is organizing
the conference in partnership with the Warsaw Stock Exchange and
Deloitte. For more information visit: http://lscwarsaw.com.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of biologics for the prevention
and treatment of serious infectious diseases. The Company is
developing an oral enzyme for the prevention of C. difficile
infections, and a series of monoclonal antibody therapies for the
treatment of Pertussis and Acinetobacter infections.
In addition, the Company is developing a drug candidate for the
treatment of relapsing-remitting multiple sclerosis and cognitive
dysfunction in multiple sclerosis. For more information, please
visit Synthetic Biologics' website at
www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile
device app, which allows users access to the Company's SEC
documents, press releases and events, please click on the following
links to download the IRapp on your iPhone and iPad or your Android
mobile device.